{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000035","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.853378+00:00","generated_at":"2026-06-18T07:05:55.531935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Caribou Q4 net loss $27M; cash $317M; CB-010 data update planned H2 2023","bullets":["Net loss of $27.0M in Q4 2022 and $99.4M for full year 2022, vs. $18.5M and $66.9M in 2021.","Cash, equivalents, and marketable securities $317.0M as of Dec 31, 2022; runway into 2025.","CB-010 ANTLER trial: all 6 pts at dose level 1 achieved complete response; 6-month CR in 3/6.","CB-011 CaMMouflage trial recruiting at dose level 1 for r/r multiple myeloma; CB-012 IND planned H2 2023.","R&D expenses $25.7M in Q4 2022 vs. $15.1M in Q4 2021, driven by pipeline advancement and headcount."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000035","json":"https://secwatch.observer/filing/0001619856-23-000035.json","markdown":"https://secwatch.observer/filing/0001619856-23-000035.md","text":"https://secwatch.observer/filing/0001619856-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/0001619856-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/crbu-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:05:55.531935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bee78f5af3b9a82d14b5f2ce871e575f64f707a8","claim":"Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 9, 2023, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/0001619856-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}